Shigemi Sugiki, MD
Ophthalmology · Honolulu, HINPI 1447350038
Payments from drug & device makers
Across 41 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$132
- Aerie Pharmaceuticals, Inc.$121
- Novartis$87
- Alcon$84
- AbbVie$79
- Bausch & Lomb, A Division Of Bausch Health US, LLC$61
- plus $192 from 5 others
What the payments were for
- Food & beverage$755100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 6 | $132 |
| Aerie Pharmaceuticals, Inc. | 6 | $121 |
| Novartis | 6 | $87 |
| Alcon | 4 | $84 |
| AbbVie(2 entities) | 4 | $79 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $61 |
| Kala Pharmaceuticals, Inc. | 4 | $57 |
| Bausch & Lomb Americas Inc. | 2 | $45 |
| Amgen | 2 | $40 |
| Johnson & Johnson Vision Care, Inc. | 2 | $36 |
| Harrow Eye, LLC | 1 | $13 |
How this compares
$755 in reported general payments places this provider in the 30th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 24 | $26,107 |
| VyzultaLatanoprostene Bunod | 22 | $17,688 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $14,849 |
| Timolol Maleate | 126 | $9,045 |
| Latanoprost | 186 | $7,215 |
| Brimonidine Tartrate | 17 | $2,558 |
| Dorzolamide Hcl | 32 | $1,002 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $121 | $40,95637 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $45 | $17,68822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Carlton YuenHonolulu$440K
- Neda NikpoorHonolulu$322K
- Alan FaulknerHonolulu$207K
- Michael BennettHonolulu$190K
- Jeffrey PetersonHonolulu$85K
- Rupa WongHonolulu$72K
- Worldster LeeHonolulu$30K
- Elysse TomHonolulu$20K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.